Aslan turns focus to biliary tract cancer as lead drug flops in PhII gastric cancer study
About a year after securing the full rights to develop and commercialize varlitinib from Array BioPharma $ARRY, Aslan Pharma $ALSN said the drug failed to confer a statistically significant reduction in tumors of patients with gastric cancer in a mid-stage study.
The Singapore-based company — which is run by former BD chief for AstraZeneca Carl Firth and went public in an underwhelming IPO last May — has essentially abandoned testing the experimental drug in patients with gastric cancer and will concentrate on studies in biliary tract cancer and other indications, it said on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.